Response of Caki-1 tumors to bevacizumab (2 mg/kg, twice a week for 2 weeks), CA4P (A) or OXi4503 (B) (100 mg/kg or 25 mg/kg respectively, three times a week for 2 weeks) or the combination of an angiogenesis-inhibiting agent and Tumor-Vascular Disrupting Agent (median tumor responses of groups of 8–10 mice). Controls (■), bevacizumab (□), CA4P (○), OXi4503 (△), bevacizumab + CA4P (●), bevacizumab + OXi4503 (▲) (redrawn with permission).145